glp 1 compounding ban New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our What Are Compounded GLP-1 Medications?

Approved GLP-RAs In 2005, Exendin-4 (Exenatide/ BYETTA), the world's first GLP-1RA, was approved by the FDA for the adjuvant treatment of type 2 diabetes with two injections per day (BID)

The report also discusses safety controversies (such as past concerns about pancreatitis and thyroid tumors) and how they have been addressed by research and regulatory reviews

Co-prescribed SGLT2 inhibitors or diuretics are more likely causes of increased urination than GLP-1 medications themselves

Semaglutide has also demonstrated cardiovascular benefits in people with overweight or obesity and established cardiovascular disease